未名医药：子公司上海未名拟向固康药业增资人民币4500万元，取得其51%股权

Core Viewpoint - The company, Weiming Pharmaceutical, is increasing its stake in Gukang Pharmaceutical by investing RMB 45 million to acquire 51% equity, aiming to enhance its competitive edge in the pharmaceutical industry [1] Group 1: Investment Details - Weiming Pharmaceutical's wholly-owned subsidiary, Shanghai Weiming, plans to invest RMB 45 million in Gukang Pharmaceutical [1] - The investment will result in Gukang Pharmaceutical becoming a subsidiary of Shanghai Weiming [1] - The valuation for the investment is based on Gukang Pharmaceutical's audited shareholder equity as of April 30, 2025 [1] Group 2: Strategic Intent - The purpose of this investment is to improve the pharmaceutical industry chain layout [1] - The company aims to integrate high-quality internal and external resources [1] - The investment is expected to enhance the company's core competitiveness and overall industry advantages [1]